SER-252 (POZ-apomorphine) in combination with enFuse

September 9, 2026: Serina Therapeutics (NYSE: SER) said the independent Safety Monitoring Committee recommended advancing SER-252 into Cohort 2 of its ongoing Phase 1b registrational study in advanced Parkinson’s disease after a blinded review of Cohort 1 safety and tolerability data.

SER-252 is a long-acting subcutaneous apomorphine formulation. Cohort 1, the lowest-dose single-ascending-dose cohort, enrolled eight patients with Parkinson’s disease and motor fluctuations in a randomized, double-blind, placebo-controlled 3:1 study versus placebo. Blinded observations showed a pharmacokinetic profile consistent with sustained apomorphine exposure and sustained periods of improved motor function in individual patients on exploratory measures, including MDS-UPDRS motor scores and structured motor-state assessments. Safety and tolerability supported continued dose escalation.

The Phase 1b SER-252-1b study includes a single-ascending-dose portion with five cohorts (n=40) and a multiple-ascending-dose portion with up to three cohorts (n=48) across sites in the U.S., Australia, South Korea, and Taiwan. Serina said topline data from the single-ascending-dose portion are expected in the first half of 2027.